The clinical gap ChondroFiller is designed to fill

If conservative treatment — physiotherapy, anti-inflammatory medication, activity modification — has stopped providing meaningful relief, but the joint is nowhere near requiring replacement, there is a specific clinical window that ChondroFiller is designed to occupy. Patients in this middle ground often feel they have run out of options when, in practice, they may be the most suitable candidates for this type of intervention.

The treatment works as an ultrasound-guided injectable collagen scaffold placed into a focal area of cartilage damage during an outpatient appointment. Because it does not require surgery, the eligibility bar is broader than for procedures such as autologous chondrocyte implantation — patients who are not surgical candidates are not automatically excluded.

The underlying clinical logic is structural: ChondroFiller requires a well-contained defect sitting within a joint that is mechanically stable and surrounded by viable cartilage tissue. Without those conditions, the scaffold cannot recruit the body's own repair cells effectively. That biological precondition — not age or fitness for theatre — is what defines whether someone falls into this window.

What your cartilage defect needs to look like

The structural criteria fall into a clear framework across four dimensions: how deep the damage is, how large the affected area is, how the damage was caused, and how old the patient is.

Depth and grade. ChondroFiller's CE-mark indication covers ICRS (Outerbridge) Grade III and IV focal chondral defects — in plain terms, partial to full-thickness cartilage loss within a localised area. Where OA-pattern damage is the clinical picture, the equivalent benchmark is Kellgren-Lawrence grades I to III. Grade I and II lesions typically fall below the treatment threshold: the scaffold's mechanism — matrix-induced chondrogenesis, which recruits the body's own progenitor cells from surrounding tissue — requires meaningful structural loss to operate on. Surface-level wear without significant depth does not meet the indication.

Size and containment. The established clinical boundary is a defect up to 6 cm². Beyond this, the available cartilage border becomes insufficient to anchor scaffold integration. Defects that are too extensive, affect multiple compartments, or lack a viable surrounding cartilage rim sit outside the indication for the same reason: there is no intact host tissue for the scaffold to work with.

Aetiology. The cause of the defect does not narrow eligibility — traumatic injury, sport-related damage, and early-to-moderate degenerative wear are all appropriate aetiologies.

Age. There is no published upper age limit. Patients aged 40 to 65 who maintain an active lifestyle tend to show the strongest clinical results in available evidence, but age alone is not a disqualifier.

Why the surrounding joint matters as much as the defect

Cartilage damage does not exist in isolation — the joint around it must be capable of distributing load evenly for any repair process to consolidate. This is why the mechanical environment functions as its own candidacy axis, separate from defect grade or size.

Limb malalignment exceeding 5°, unaddressed ligament instability, and meniscal tears all fall into this category. The principle is straightforward: placing a scaffold into a mechanically hostile joint is comparable to patching a surface while the structure beneath it remains unstable — the repair cannot hold if the forces acting on it are wrongly distributed. These factors are disqualifiers in their untreated state, not permanent exclusions. Patients who have malalignment or instability may remain viable candidates once the underlying mechanical problem has been corrected, either before or alongside the ChondroFiller procedure.

On the positive side of this axis, preserved joint space with moderate pain represents the outcome-predictive phenotype. Clinical assessment using VAS pain scoring and WOMAC function scores helps identify patients whose joints retain enough structural integrity for meaningful improvement. Bone-on-bone contact, by contrast, indicates advanced compartmental loss — a scenario that shifts the clinical conversation away from scaffold-based repair entirely.

Conditions that rule ChondroFiller out

Several factors place ChondroFiller outside what is clinically appropriate, and it is worth being clear about which represent absolute bars and which are relative considerations that may shift with circumstances.

Joint and local conditions. Advanced or generalised osteoarthritis — where cartilage loss is widespread across multiple compartments rather than contained within a focal area — removes the viable host tissue that scaffold integration depends on. The same applies to inflammatory arthropathies: rheumatoid and psoriatic arthritis create a systemically inflamed joint environment that disrupts the biological repair process regardless of defect characteristics. Active infection within or around the target joint, and the presence of a periarticular tumour, are absolute contraindications without exception.

Biological and allergy. ChondroFiller is derived from murine (rat) type I collagen. A known hypersensitivity to murine or bovine collagen proteins is an absolute contraindication — there is no clinical workaround for this sensitivity.

Systemic and situational. A broader cluster of systemic conditions also precludes treatment: gout, active malignancy, haematological or neurological disorders, and active bleeding disorders or dependency on anticoagulant therapy. Each of these affects the biological healing environment, coagulation safety, or both. Pregnancy is excluded on the basis of an absence of safety data rather than any established evidence of harm — a precautionary position rather than a confirmed risk.

Most of these factors are uncommon in the 40–65 active-lifestyle population for whom ChondroFiller is primarily indicated. Where the treatment does not fit, other pathways exist; a consultant assessment will identify which direction is appropriate.

How candidacy is assessed before treatment

An initial consultation brings together imaging, symptom review, and physical assessment rather than relying on any single test. In practice, MRI is the starting point — it provides the clearest picture of defect grade, lesion dimensions, the health of the cartilage border around the defect, and how much joint space remains. A weight-bearing X-ray is typically taken alongside to support Kellgren-Lawrence grading and identify any bony changes that MRI alone may not fully capture.

Symptom scoring forms a second strand. VAS and WOMAC assessments, both touched on in the mechanical context earlier, serve a practical function at this stage: they establish a documented baseline that makes post-treatment comparison meaningful, and they help confirm that the patient's symptom profile aligns with what the evidence base shows is most likely to respond.

Biomechanical assessment is the third element. Where gait asymmetry, loading pattern, or movement compensation is suspected — particularly if imaging hints at alignment issues — objective evaluation adds precision. At MSK Doctors, MAI Motion® markerless motion-capture analysis can provide this kind of quantified biomechanical data as part of the pre-treatment picture, without the need for sensors or markers.

The consultation draws these threads together: defect characteristics, joint mechanics, biological profile, and the patient's own activity goals. If the clinical picture supports it, the conclusion at this stage is confirmation that the outpatient ultrasound-guided injection pathway is appropriate — a practical next step, not a surgical commitment.

Taking the next step at MSK Doctors

For patients in Lincolnshire and the wider non-London catchment, MSK Doctors runs dedicated musculoskeletal clinics in Sleaford (NG34) and Grantham (NG31), both of which offer ChondroFiller candidacy assessment as part of a full cartilage-care evaluation. No GP referral is needed, and there are no NHS-style waiting lists — the group is CQC-registered and rated Good across all five key domains. Patients based in London can access the same clinical pathway through the London Cartilage Clinic, the group's London arm.

You can book a consultation online at mskdoctors.com without a referral.